Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

1448956

USP

Mycophenolate mofetil

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

(4E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester, RS 61443, TM-MMF

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C23H31NO7
CAS Number:
128794-94-5
Molecular Weight:
433.49
MDL number:
MFCD00867568
UNSPSC Code:
41116107
PubChem Substance ID:
329750505
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

mycophenolate

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

15-25°C

SMILES string

COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN3CCOCC3

InChI

1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+

InChI key

RTGDFNSFWBGLEC-SYZQJQIISA-N

Gene Information

human ... IMPDH1(3614) , IMPDH2(3615)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Biochem/physiol Actions

Mycophenolate mofetil is a prodrug of mycophenolic acid (Cat. # M5255) that is cleaved by nonspecific esterases in vivo to produce the parent compound. Mycophenolic acid blocks inosine monophosphate dehydrogenase and is a potent immunosuppresive agent.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0000489

Mycophenolate mofetil, European Pharmacopoeia (EP) Reference Standard

Y0000519

Mycophenolate mofetil for peak identification, European Pharmacopoeia (EP) Reference Standard

1448967

Mycophenolate Mofetil Related Compound A, United States Pharmacopeia (USP) Reference Standard

1448978

Mycophenolate Mofetil Related Compound B, United States Pharmacopeia (USP) Reference Standard

1448989

Mycophenolate sodium, United States Pharmacopeia (USP) Reference Standard

Y0002200

Mycophenolate for system suitability, European Pharmacopoeia (EP) Reference Standard

PHR2776

Mycophenolate Mofetil Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material, pkg of 100 mg

PHR3211

Mycophenolate Sodium, pharmaceutical secondary standard, certified reference material

Signal Word

Danger

Hazard Statements

H302,H360D,H372,H410

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 1B - STOT RE 1

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A D Goralczyk et al.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 12(10), 2601-2607 (2012-07-21)
Liver transplant recipients are at high risk of developing acute and chronic renal failure. Moreover, introduction of the model for end-stage liver disease (MELD) score for primary allocation of liver grafts favors patients with pretransplant kidney dysfunction, which in turn
John Seal et al.
Transplantation, 99(3), 623-628 (2014-08-26)
There is a paucity of contemporary data describing the results of pancreas retransplantation (PRT). As a measure of utility, we wished to determine whether PRT could produce equivalent short-term and long-term recipient outcomes to primary pancreas after kidney (PAK) transplantation.
Andrew Bentall et al.
Transplantation, 98(10), 1089-1096 (2014-06-10)
ABO-incompatible kidney transplantations (ABOiKTxs) seem to have better long-term outcomes than positive crossmatch kidney transplantations (+XMKTxs). This study aimed to assess the differences in chronic injury on histologic findings on 1- and 5-year surveillance biopsies and the clinical outcomes in
K Budde et al.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 14(12), 2796-2806 (2014-10-04)
This Phase III randomized trial examined efficacy and safety of a novel once-daily extended-release tacrolimus formulation (LCP-Tacro [LCPT]) versus twice-daily tacrolimus in de novo kidney transplantation. Primary efficacy end point was proportion of patients with treatment failure (death, graft failure
P Satwani et al.
Leukemia, 29(2), 448-455 (2014-06-19)
The outcome of children, adolescents and young adults (CAYA) with poor-risk recurrent/refractory lymphoma is dismal (⩽30%). To overcome this poor prognosis, we designed an approach to maximize an allogeneic graft vs lymphoma effect in the setting of low disease burden.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service